Biopharmaceutical sponsors should make urgent decisions now to plan for continued clinical research in the coming months.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
COVID spotlights the troubling disparity in clinical research representation. How can we remove these barriers?
Implementing disclosure and data transparency policies and procedures represents an opportunity for sponsors, rather than an obligation.
Sonja Wustrack, OM1, highlights a new clinical study automation platform to support critical data collection and real-world evidence.
RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.
Tufts Center for the Study of Drug Development and Biogen recently conducted a study to inform growing interest in improving diversity of clinical trial participation. The results of this research provide insights into increasing the community of minority investigators and study staff and presenting greater access to clinical trials among minority study volunteers.
Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.
The benefits of working with an institutional biosafety committee in CGT research.
Phesi and Tufts CSDD share results from research on operating practices that can be improved.
Approaching protocol design and operational planning with patient empathy.
Understanding the role of social determinants on clinical trial participation and trust.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
Improved diversity in clinical trials can be achieved by exploring opportunities for research in developing countries that have not historically participated in large-scale, industry-sponsored clinical trials.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.
A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia.
Amid CVS’ surprise exit from the clinical research space and the ensuing broader questions, study investigates the benefits of pharmacy chain involvement—along with the concerns and barriers to adoption.
Providing patients with more flexibility in how they choose to participate in trials.
Higher costs headline list of new challenges faced by CROs and sponsors.
Five strategies to reduce risk and achieve deadlines.
As many countries slowly progress with the “New Normal,” researchers and healthcare providers are assessing digital/virtual approaches that could reinstate clinical trials.
Highlighting the inherent risks associated with subtle biases in clinical research practice, as well as the most proven strategy for mitigating each risk.
Past decades have shown gender-based differences in clinical trial results are often overlooked when considering safety and effectiveness.
The ACT EU initiative aims to develop the European Union further as a competitive center for innovative clinical research.
Biotechs can successfully overcome bottlenecks in time-to-market for new drugs by embracing contracting innovations with the same passion applied to research breakthroughs.
Wed, Sep 7, 2022 11:00am EST | 8:00am PST | 4pm BST | 5:00pm CEST Decentralized Clinical Trials (DCT) is one of the hottest buzzwords in Life Sciences and Connected Health organizations today. Like any new approach, challenges and roadblocks are common and knowing how to solve for them will empower your organization to accelerate your trial deployment, speeding return of results and time to market.